R&D | January 02, 2025
Huadong Medicine and SynerK to jointly develop a novel siRNA drug SNK-2726
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
Puri is an accomplished leader and financial sector veteran with over four decades of experience
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Thyrocare becomes first national diagnostic chain with 100% of its labs with NABL accreditation
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Subscribe To Our Newsletter & Stay Updated
